SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome: Thus, despite different severities of the phenotype, all of the listed features render the DAT-KO mouse a suitable and readily available model for testing novel treatment approaches for pharmacoresistant DTDS, including gene therapy.